Germany · Delayed Price · Currency is EUR Shield Therapeutics Statistics
Total Valuation
FRA:1JS has a market cap or net worth of EUR 117.16 million. The enterprise value is 130.64 million.
| Market Cap | 117.16M |
| Enterprise Value | 130.64M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.06B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +19.74% |
| Shares Change (QoQ) | +32.96% |
| Owned by Insiders (%) | 1.71% |
| Owned by Institutions (%) | 31.78% |
| Float | 408.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.32 |
| PB Ratio | -9.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.24 |
| P/OCF Ratio | 27.23 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.22 |
| EV / Sales | 3.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 30.37 |
Financial Position
The company has a current ratio of 0.83
| Current Ratio | 0.83 |
| Quick Ratio | 0.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 5.35 |
| Interest Coverage | -2.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -16.77% |
| Return on Invested Capital (ROIC) | -55.83% |
| Return on Capital Employed (ROCE) | -120.79% |
| Revenue Per Employee | 560,841 |
| Profits Per Employee | -287,064 |
| Employee Count | 63 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 3.98 |
Taxes
In the past 12 months, FRA:1JS has paid 669,279 in taxes.
| Income Tax | 669,279 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +153.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +153.03% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 52.86 |
| Average Volume (20 Days) | 884 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:1JS had revenue of EUR 35.33 million and -18.09 million in losses. Loss per share was -0.02.
| Revenue | 35.33M |
| Gross Profit | 17.08M |
| Operating Income | -12.44M |
| Pretax Income | -17.42M |
| Net Income | -18.09M |
| EBITDA | -12.24M |
| EBIT | -12.44M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 9.21 million in cash and 23.03 million in debt, giving a net cash position of -13.82 million.
| Cash & Cash Equivalents | 9.21M |
| Total Debt | 23.03M |
| Net Cash | -13.82M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -12.65M |
| Book Value Per Share | -0.01 |
| Working Capital | -7.36M |
Cash Flow
In the last 12 months, operating cash flow was 4.30 million and capital expenditures -852, giving a free cash flow of 4.30 million.
| Operating Cash Flow | 4.30M |
| Capital Expenditures | -852 |
| Free Cash Flow | 4.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 48.34%, with operating and profit margins of -35.20% and -51.18%.
| Gross Margin | 48.34% |
| Operating Margin | -35.20% |
| Pretax Margin | -49.29% |
| Profit Margin | -51.18% |
| EBITDA Margin | -34.65% |
| EBIT Margin | -35.20% |
| FCF Margin | 12.17% |
Dividends & Yields
FRA:1JS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.74% |
| Shareholder Yield | -19.74% |
| Earnings Yield | -15.44% |
| FCF Yield | 3.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:1JS has an Altman Z-Score of -6.08 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.08 |
| Piotroski F-Score | 4 |